Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampicillin/Sulbactam vs Cefoperazone/Sulbactam for MDR Acinetobacter Baumannii
NCT07118384Recruiting
- Sponsor
- Cairo University
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
Randomised trial of cefoperazone + sulbactam in Acinetobacter baumannii infection (2 arms), sponsored by Cairo University. Primary endpoint: Treatment effectiveness Based on Clinical improvement at 5 days. Started May 2025; status: recruiting.
02
Drugs
cefoperazone + sulbactam
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT07118384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118384.